A 3-year, multicenter, randomized, treat-to-target study of 708 insulin-naïve patients with type 2 diabetes. A total of 234 patients were randomized to Levemir® and were intensified with NovoLog® if A1C was >10% after 1 measurement or ≥8% for 2 consecutive measurements at or after 24 weeks, or if A1C was >6.5% at 1 year. At study end, 82% of patients had been intensified with NovoLog®. The results of this arm of the study are shown here. In addition, 239 patients were randomized to NovoLog® and 235 patients were randomized to biphasic insulin aspart 30 (results not shown). All insulin was delivered by FlexPen®.2,3
a Data are representative of all patients in the Levemir®-initiated arm. Sulfonylureas were discontinued.
b Levemir® was initiated at beginning of study and NovoLog® was added 3x daily with each meal.
c Doses of Levemir® and NovoLog® were titrated per study protocol.
d Baseline A1C was 8.4% Â± 0.8%.3
Adapted from Holman et al, 2009.2